Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

被引：3
|
作者：
Moreno, V. [1 ]
Brana, I. [2 ]
Sepulveda Sanchez, J. M. [3 ]
Vieito Villar, M. [4 ]
Hernandez Guerrero, T. [1 ]
Doger, B. [1 ]
Saavedra, O. [2 ]
Pinto, A. [5 ]
Carlo Stella, C. [6 ]
Italiano, A. [7 ]
Michot, J-M. [8 ]
Musuraca, G. [9 ]
Sarmiento, R. [10 ]
De Alvaro, J. [10 ]
Zuraek, M. [11 ]
Sanchez-Perez, T. [10 ]
Aronchik, I. [11 ]
Filvaroff, E. [11 ]
Hanna, B. [11 ]
Nikolova, Z. [10 ]
机构：
[1] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
[2] Hosp Univ Vall dHebron, Barcelona, Spain
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] Hosp Univ Vall Hebron, Barcelona, La Coruna, Spain
[5] Ist Nazl Tumori IRCSS Fdn Pascale, Naples, Italy
[6] Humanitas Clin & Res Ctr, Humanitas Canc Ctr, Milan, Italy
[7] Ctr Reg Lutte Canc Bordeaux & Sud Ouest, Inst Bergonie, Bordeaux, France
[8] Inst Gustave Roussy, Dept Hematol, Villejuif, France
[9] Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy
[10] Celgene, Summit, NJ USA
[11] Bristol Myers Squibb, Summit, NJ USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.01.025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16O
引用
收藏
页码：S5 / S5
页数：1
相关论文
共 50 条
  • [21] Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)
    Abrisqueta, Pau
    Sancho, Juan-Manuel
    Cordoba, Raul
    Persky, Daniel O.
    Andreadis, Charalambos
    Huntington, Scott F.
    Carpio, Cecilia
    Giles, Daniel Morillo
    Wei, Xin
    Li, Ying Fei
    Zuraek, Marlene
    Burgess, Michael R.
    Hege, Kristen
    Martin, Alejandro
    BLOOD, 2019, 134
  • [22] Activity of R-DHAOX regimen in patients (pts) affected by relapsed/resistant non-Hodgkin's lymphoma (NHL).
    Berretta, M
    Rupolo, M
    Michieli, M
    Spina, M
    Tirelli, U
    BLOOD, 2003, 102 (11) : 291B - 291B
  • [23] Phase II clinical study of bortezomib (VELCADE®) in patients (pts) with relapsed refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD).
    Strauss, SJ
    Maharaj, L
    Stec, J
    Boral, A
    Trehu, E
    Schenkein, D
    Joel, SP
    Lister, TA
    BLOOD, 2004, 104 (11) : 389A - 389A
  • [24] CC-95775, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients with advanced solid tumors (STs): Results of a phase 1 study
    Lesimple, Thierry
    de Miguel, Maria Jose
    Le Tourneau, Cristophe
    Ponz-Sarvise, Mariano
    Sablin, Marie Paule
    Benito, Diego Salas
    Hanna, Bishoy
    Chang, Henry
    Wei, Xin
    Garcia, Marta Ocejo
    Lardelli, Pilar
    Sanchez, Tania
    Palau, Josep Lluis Parra
    Nikolova, Zariana
    Calvo, Emiliano
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [25] Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL)
    Stathis, A.
    Hotte, S.
    Hirte, H.
    Chen, E. X.
    Webster, S.
    Iacobucci, A.
    McGill, S.
    Wang, L.
    Espinoza-Delgado, I.
    Siu, L. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).
    Morschhauser, Franck
    Flinn, Ian
    Advani, Ranjana H.
    Sehn, Laurie Helen
    Kolibaba, Kathryn S.
    Press, Oliver W.
    Salles, Gilles A.
    Diefenbach, Catherine S. Magid
    Tilly, Herve
    Assouline, Sarit E.
    Chen, Andrew Tzong-Yow
    Dreyling, Martin H.
    Hagenbeek, Anton
    Zinzani, Pier Luigi
    Cheson, Bruce D.
    Yalamanchili, Sreenivasu
    Lu, Dan
    Chai, Akiko
    Chu, Yu-Waye
    Sharman, Jeff Porter
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma
    Bond, David A.
    Huang, Ying
    Christian, Beth A.
    Jaglowski, Samantha
    Benson, Don
    Alinari, Lapo
    Baiocchi, Robert A.
    Cohen, Jonathon B.
    Blum, Kristie A.
    Maddocks, Kami J.
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1750 - 1753
  • [28] Phase I clinical study of Bruton's tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
    Lee, Ning
    Li, Yingfu
    Mao, Yong
    Liu, Guanfeng
    Li, Jiang
    Liu, Qingchun
    CANCER RESEARCH, 2024, 84 (07)
  • [29] A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results
    Hernandez-Ilizaliturri, Francisco J.
    Flinn, Ian W.
    Kuruvilla, John
    Assouline, Sarit E.
    Ulrickson, Matthew L.
    Christian, Beth A.
    Landsburg, Daniel J.
    Stuart, Monic
    Lowman, Henry
    Levin, Nancy
    BLOOD, 2020, 136
  • [30] A Lysa Phase II Study of Oral JAK1/2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)
    Van Den Neste, Eric W.
    Andre, Marc
    Gastinne, Thomas
    Stamatoullas, Aspasia
    Haioun, Corinne
    Belhabri, Amine
    Reman, Oumedaly
    Casasnovas, Olivier
    Ghesquieres, Herve
    Verhoef, Gregor
    Claessen, Marie-Jose
    Poirel, Helene A.
    Copin, Marie-Christine
    Dubois, Romain
    Vandenberghe, Peter
    Stoian, Ioanna-Andrea
    Cottereau, Anne Segolene
    Knoops, Laurent
    Morschhauser, Franck
    BLOOD, 2016, 128 (22)
12345